This retrospective cross-sectional study examines the epidemiology and predictive factors associated with ESBL-producing E. coli and its concomitant fluoroquinolone resistance among community-acquired clinical isolates in Mexico. The analysis included a sample size of 244 isolates. The study is categorized as a review of observational data rather than a randomized trial.
Key findings indicate that 165 of 244 isolates were ESBL producing, representing 68% of the total. Resistance among these ESBL-producing isolates was observed at 30% for levofloxacin and 35% for ciprofloxacin. The highest frequency of ESBL production occurred in the 20 to 39 age group. Additionally, 73% of ESBL-positive isolates were obtained from women, though the association was non-significant with an OR of 1.29 and a 95% CI of 0.72 to 2.31. Urine samples showed the highest concentration of ESBL-positive isolates.
The authors underscore the need to strengthen antimicrobial use management and local surveillance strategies. Safety data, including adverse events and tolerability, were not reported. The study does not establish causality, and limitations regarding the observational nature of the data are inherent to the design.
Practice relevance is directed toward monitoring resistance patterns in community settings. Clinicians should interpret these resistance rates as indicators for empirical therapy choices in specific demographic groups.
View Original Abstract ↓
Urinary tract infections (UTIs) are among the most common infectious diseases worldwide, with Escherichia coli being the predominant uropathogen. The increasing prevalence of extended-spectrum beta-lactamase (ESBL)producing strains and their association with fluoroquinolone resistance pose a significant challenge to empirical therapy, particularly in community settings. The aim of this study was to determine the epidemiology and predictive factors associated with ESBL-producing E. coli and its concomitant fluoroquinolone resistance in community acquired clinical isolates. A retrospective cross-sectional study was conducted analyzing 244 clinical E. coli isolates. Demographic and microbiological data were collected, including age, sex, sample type, and antibiotic susceptibility. Associations between variables and ESBL production were assessed using Pearson's chi squared test, and odds ratios (ORs) with 95% confidence intervals (CIs) were calculated. Of the isolates, 165 (68%) were ESBL producing. A significant association was observed between age group and ESBL production (p < 0.001), with the highest frequency in the 20 to 39 age group. Most ESBL positive isolates were obtained from women (73%), although odds ratio (OR) analysis suggested a non-significant trend toward a higher probability in men (OR = 1.29; 95% CI: 0.72 to 2.31). High rates of fluoroquinolone resistance were identified among the ESBL producing isolates, with 30% resistance to levofloxacin and 35% to ciprofloxacin (p < 0.001). Urine samples showed the highest concentration of ESBL positive isolates, with a significant association between sample type and resistance (p < 0.001). The high prevalence of ESBL producing E. coli and its concomitant resistance to fluoroquinolones highlight a critical challenge for the empirical treatment of urinary tract infections in Mexico, underscoring the need to strengthen antimicrobial use management and local surveillance strategies.